Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.83 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.83 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.83 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.83 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.83 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.83 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | KDM4A | O75164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008757 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL770290 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| Phenylheptanoic Acid SCHEMBL535246 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL1290374 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL2552651 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| Phenylheptanoic Acid SCHEMBL7655508 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL2551105 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL2548842 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL1007173 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL2553009 | 1.00 | MAPT (1.00) | MAPTRXFP1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011124228-A1 | A BIOCIDAL POLYOLEFIN YARN WITH 3-12 FILAMENTS | VESTERGAARD FRANDSEN SA (CH) | 2011-10-13 | — | — | WO | claimed |
| WO-2011124227-A1 | BIOCIDAL ACID-ADJUSTED POLYMER WITH POLYPROPYLENE | VESTERGAARD FRANDSEN SA (CH) | 2011-10-13 | — | — | WO | claimed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| WO-2012162020-A1 | STABILIZED BLENDS CONTAINING ANTIOXIDANTS | THE LUBRIZOL CORPORATION (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162027-A1 | STABILIZED BLENDS CONTAINING FRICTION MODIFIERS | THE LUBRIZOL CORPORATION (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011124227-A1 | BIOCIDAL ACID-ADJUSTED POLYMER WITH POLYPROPYLENE | VESTERGAARD FRANDSEN SA (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-7795207-B2 | Lipopeptide compositions | MERLION PHARMACEUTICALS GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20070219124-A1 | Lipopeptide compositions | COMBINATURE BIOPHARM AG (DE) | 2007-09-20 | — | — | US | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MAPT 3973/4885RXFP1 3075/4885HDAC1 1399/4885 |
| US-20070219124-A1 | Lipopeptide compositions | NOD2, IAPP, PTMS | MAPT 3729/4885RXFP1 1379/4885HDAC1 4788/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MAPT 4094/4885RXFP1 1262/4885HDAC1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.